GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Capex-to-Operating-Income

Anxo Pharmaceutical Co (ROCO:6677) Capex-to-Operating-Income : 1.37 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Anxo Pharmaceutical Co's Capital Expenditure for the six months ended in Jun. 2023 was NT$-27.17 Mil. Its Operating Income for the six months ended in Jun. 2023 was NT$19.79 Mil.

Hence, Anxo Pharmaceutical Co's Capex-to-Operating-Income for the six months ended in Jun. 2023 was 1.37.


Anxo Pharmaceutical Co Capex-to-Operating-Income Historical Data

The historical data trend for Anxo Pharmaceutical Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Capex-to-Operating-Income Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.64 0.28 0.85 2.54

Anxo Pharmaceutical Co Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 0.39 - 0.15 1.37

Competitive Comparison of Anxo Pharmaceutical Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Capex-to-Operating-Income falls into.



Anxo Pharmaceutical Co Capex-to-Operating-Income Calculation

Anxo Pharmaceutical Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-15.772) / 6.21
=2.54

Anxo Pharmaceutical Co's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-27.174) / 19.791
=1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anxo Pharmaceutical Co  (ROCO:6677) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Anxo Pharmaceutical Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Anxo Pharmaceutical Co (ROCO:6677) Business Description

Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines